Abstract:
BACKGROUND:This meta-analysis of randomized controlled trials aimed to comprehensively assess the efficacy and toxicity of cyclin-dependent kinase (CDK) 4/6 inhibitors in advanced breast cancer (ABC) with hormone-receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) disease. METHODS:We performed a systematical search using Cochrane Library, PubMed, Embase, and Web of Science up to March 2018. Only phase 2 and 3 randomized clinical trials assessing the efficacy and toxicity of the combination regimen of CDK4/6 inhibitors plus hormone therapy compared with hormone therapy alone were eligible for this meta-analysis. The pooled analyses of relative risk (RR) and hazard ratio were carried out by Stata software. RESULTS:A total of 7 randomized controlled trials including 3854 patients with HR+/HER2- ABC were included in this meta-analysis. The pooled hazard ratio for progression-free survival was 0.54 (95% confidence interval, 0.49-0.59; P < .001), and the pooled RR for the objective response rate in all intent-to-treat patients was 1.51 (95% confidence interval, 1.26-1.81; P < .001). The pooled RRs for all grade adverse events (AEs) and grade 3/4 AEs were 1.07 (95% confidence interval, 1.03-1.11; P < .001) and 2.81 (95% confidence interval, 2.54-3.11; P < .001), respectively. However, to investigate the influence of CDK4/6 inhibitors on overall survival, sufficient follow-up is still needed. CONCLUSION:CDK4/6 inhibitors plus hormone therapy can significantly prolong the progression-free survival of patients with HR+/HER2- ABC and improve the objective response rate compared to conventional hormone therapy alone. The combined regimen results in a higher risk of AEs, especially grade 3/4 AEs.
journal_name
Clin Breast Cancerjournal_title
Clinical breast cancerauthors
Deng Y,Ma G,Li W,Wang T,Zhao Y,Wu Qdoi
10.1016/j.clbc.2018.04.017subject
Has Abstractpub_date
2018-10-01 00:00:00pages
e943-e953issue
5eissn
1526-8209issn
1938-0666pii
S1526-8209(17)30798-Xjournal_volume
18pub_type
杂志文章,meta分析abstract:BACKGROUND:Medical isotopes are required for sentinel node lymphoscintigraphy in breast cancer, but are in critical shortage. Our center uses a modification of the standard SC, called CRC, that has been shown to require less medical isotope for the same procedure. Our objective was to determine if there was a significa...
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.1016/j.clbc.2014.07.006
更新日期:2015-02-01 00:00:00
abstract:BACKGROUND:Causes of racial disparities in breast cancer survival remain unclear. This study assesses overall survival (OS) after diagnosis between black and white women and examines factors that might correlate with this disparity. PATIENTS AND METHODS:Data were obtained from the Medical College of Georgia Tumor Regi...
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.3816/CBC.2010.n.008
更新日期:2010-02-01 00:00:00
abstract::The potential for cardiac toxicity in association with targeted biologic agents was first observed with trastuzumab, a monoclonal antibody that targets the ErbB2/HER2 receptor. In the pivotal trial of trastuzumab in ErbB2-positive metastatic cancer, an increased incidence of serious cardiac events was observed, partic...
journal_title:Clinical breast cancer
pub_type: 杂志文章,评审
doi:10.3816/cbc.2008.s.007
更新日期:2008-03-01 00:00:00
abstract:PURPOSE:Limited outcomes exist in patients who develop an ipsilateral breast tumor recurrence (IBTR) after accelerated partial breast irradiation (APBI). The purpose of this study was to evaluate these outcomes and patterns of failure in our cohort of patients undergoing APBI. METHODS AND MATERIALS:A total of 534 pati...
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.1016/j.clbc.2012.09.006
更新日期:2012-12-01 00:00:00
abstract::Traditionally in the treatment of primary breast cancer, axillary lymph node dissection (ALND) plays an important role. However, a substantial and increasing percentage of patients appear to have no nodal involvement and have been subjected to ALND unnecessarily. The first reason to perform an ALND is axillary nodal s...
journal_title:Clinical breast cancer
pub_type: 杂志文章,评审
doi:10.3816/cbc.2002.n.034
更新日期:2002-12-01 00:00:00
abstract::Preliminary results of a phase II study of gemcitabine plus trastuzumab in previously treated (up to 3 previous regimens) metastatic breast cancer patients are presented. Patients had histologically confirmed metastatic breast cancer, with 2+ or 3+ tumor HER2 expression. Treatment consisted of gemcitabine 1200 mg/m2 o...
journal_title:Clinical breast cancer
pub_type: 临床试验,杂志文章
doi:10.3816/cbc.2002.s.004
更新日期:2002-05-01 00:00:00
abstract::Breast-conserving therapy (BCT) consists of segmental mastectomy followed by postoperative radiation therapy (RT) to the whole breast. At least 6 prospective randomized trials have proven the equivalence of BCT to mastectomy. However, BCT remains underused and, most importantly, a sizable proportion of patients with i...
journal_title:Clinical breast cancer
pub_type: 杂志文章,评审
doi:10.3816/cbc.2003.n.030
更新日期:2003-10-01 00:00:00
abstract:INTRODUCTION:For patients who have an ipsilateral breast cancer recurrence following prior breast-conserving surgery and radiation, total mastectomy generally is recommended. However, little is known about the suitability and outcomes of nipple-sparing mastectomy (NSM) with immediate breast reconstruction for the treat...
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.1016/j.clbc.2016.10.011
更新日期:2017-07-01 00:00:00
abstract:PURPOSE:HER2 gene amplification and overexpression is associated with aggressive breast cancer and poor prognosis. Accurate HER2 testing of patients with breast cancer before treatment is important to ensure that as many patients with HER2-positive breast cancer as possible receive the most appropriate treatment and th...
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.3816/CBC.2007.n.040
更新日期:2007-10-01 00:00:00
abstract:BACKGROUND:Postmenopausal women with osteoporosis had a 66% relative risk reduction for invasive breast cancer over 8 years of raloxifene therapy in the randomized, placebo-controlled 4-year MORE (Multiple Outcomes of Raloxifene Evaluation) trial and the CORE (Continuing Outcomes Relevant to Evista) trial, a 4-year fol...
journal_title:Clinical breast cancer
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.3816/CBC.2009.n.008
更新日期:2009-02-01 00:00:00
abstract::Breast cancer at age 21 is rare, even in individuals who have a genetic predisposition. These early diagnoses are usually the result of a hereditary cancer syndrome. Other contributing factors, such as chemotherapy and radiation for previous malignancies, can also increase the risk of secondary malignancies, including...
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.1016/j.clbc.2010.11.001
更新日期:2011-08-01 00:00:00
abstract::Tamoxifen reduced the risk of invasive breast cancer by 49% among women at increased risk for breast cancer in the Breast Cancer Prevention Trial P-1, and raloxifene reduced breast cancer incidence by more than 70% in the Multiple Outcomes of Raloxifene Evaluation osteoporosis trial. These findings led the National Su...
journal_title:Clinical breast cancer
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.3816/CBC.2002.n.020
更新日期:2002-06-01 00:00:00
abstract:BACKGROUND:Eribulin has efficacy in patients with progression after ≥ 1 chemotherapeutic regimen for metastatic breast cancer (MBC). A short disease-free interval (DFI) and previous use of taxanes in the neoadjuvant or adjuvant setting have been associated with worse outcomes for patients receiving first-line chemother...
journal_title:Clinical breast cancer
pub_type: 杂志文章,多中心研究
doi:10.1016/j.clbc.2018.12.012
更新日期:2019-04-01 00:00:00
abstract:INTRODUCTION:The adjuvant trastuzumab trials largely excluded women with small, node-negative, HER2-positive breast cancers. Accordingly, limited data exist regarding the effect of trastuzumab in the management of these patients. Our aim was to assess the outcomes of, and treatments administered to, women with small (≤...
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.1016/j.clbc.2014.12.012
更新日期:2015-08-01 00:00:00
abstract:BACKGROUND:Based on preclinical studies and a phase I trial of the combination of bortezomib and pegylated liposomal doxorubicin (PLD), which both showed activity in breast cancer, we conducted a phase II study of this regimen in patients with metastatic breast cancer. PATIENTS AND METHODS:Patients received bortezomib...
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.3816/CBC.2010.n.061
更新日期:2010-12-01 00:00:00
abstract:BACKGROUND:Nanoparticle albumin-bound paclitaxel (nab-P) and bevacizumab have each demonstrated efficacy in patients with MBC. This trial was designed to further develop nab-P by evaluating its efficacy and safety using every 3 weeks (q3w), every 2 weeks (q2w), or weekly scheduling in combination with bevacizumab as fi...
journal_title:Clinical breast cancer
pub_type: 杂志文章,随机对照试验
doi:10.1016/j.clbc.2013.02.008
更新日期:2013-08-01 00:00:00
abstract:BACKGROUND:Ectopic breast tissue, which includes both supernumerary breast and aberrant breast tissue, is the most common congenital breast abnormality. Ectopic breast cancers are rare neoplasms that occur in 0.3% to 0.6% of all cases of breast cancer. PATIENTS AND METHODS:We retrospectively report, using a large seri...
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.1016/j.clbc.2016.03.004
更新日期:2016-08-01 00:00:00
abstract:BACKGROUND:Novel targeted agents and combinations have become available in multiple lines of treatment for human epidermal growth factor receptor 2-positive (HER2(+)) metastatic breast cancer (MBC). In this context, alternatives to the lapatinib (L) and capecitabine (C) regimen, evaluating L combined with other cytotox...
journal_title:Clinical breast cancer
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.1016/j.clbc.2015.10.005
更新日期:2016-02-01 00:00:00
abstract:PURPOSE:Oncotype DX (ODX) predicts breast cancer recurrence risk, guiding the choice of adjuvant treatment. In many countries, access to the test is not always available. We used correlation between phenotypical tumor characteristics, quantitative classical immunohistochemistry (IHC), and recurrence score (RS) assessed...
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.1016/j.clbc.2020.04.012
更新日期:2020-10-01 00:00:00
abstract:INTRODUCTION:Dose-dense therapies have had a major effect on reducing toxicity and improving outcomes in breast cancer. A combination of TC every 3 weeks has emerged as a common chemotherapy regimen used for treatment of node-negative or lower-risk node-positive breast cancer. We tested whether it is feasible to delive...
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.1016/j.clbc.2013.10.018
更新日期:2014-06-01 00:00:00
abstract:BACKGROUND:The [18F]-fluorodeoxyglucose positron emission tomography (FDG-PET) cancer screening program is defined as cancer screening for asymptomatic subjects using FDG-PET/computed tomography with or without combination of other screening tests. The aim of this study was to analyze the detection rate and effectivene...
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.1016/j.clbc.2014.09.008
更新日期:2015-04-01 00:00:00
abstract:PURPOSE:We investigated the efficacy and toxicity of sorafenib, a multikinase inhibitor of vascular endothelial growth factor receptor tyrosine kinase, in combination with vinorelbine therapy in a phase I/II trial in patients with metastatic breast cancer. PATIENTS AND METHODS:We enrolled 11 patients in the phase I po...
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.1016/j.clbc.2013.10.013
更新日期:2014-04-01 00:00:00
abstract::The androgen receptor (AR) is increasingly considered as a potential biomarker for breast cancer. Nevertheless, the prognostic value of AR expression in patients with triple negative breast cancer (TNBC) remains controversial. Therefore, in this meta-analysis, we investigated AR expression and its impact on survival o...
journal_title:Clinical breast cancer
pub_type: 杂志文章,评审
doi:10.1016/j.clbc.2020.01.002
更新日期:2020-08-01 00:00:00
abstract:BACKGROUND:The purpose of this study was to assess the activity and safety of the combination of vinorelbine (VNR) and capecitabine (CAP) as first-line treatment in HER2-negative (HER(-)) metastatic breast cancer (MBC). PATIENTS AND METHODS:Patients (42) enrolled in trial A received intravenous (i.v.) VNR 25 mg/m2 on ...
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.1016/j.clbc.2011.11.001
更新日期:2012-02-01 00:00:00
abstract:INTRODUCTION:Unwanted clinical variation is common across the United States health care system and is particularly vexing in oncology owing to the complexity, morbidity, and high cost of the disease. Efforts to standardize care including guidelines and continuing medical education have had only limited impact. Disease-...
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.1016/j.clbc.2018.12.010
更新日期:2019-04-01 00:00:00
abstract:BACKGROUND:Adjuvant trastuzumab improves relapse-free survival in HER2-overexpressing breast cancer but is associated with cardiac toxicity. This phase II study was undertaken to determine the neoadjuvant clinical and pathologic response rate and the acute and chronic cardiac toxicity of trastuzumab given with weekly p...
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.3816/CBC.2006.n.035
更新日期:2006-08-01 00:00:00
abstract:BACKGROUND:Volume displacement techniques that use remnant breast tissue are useful in reconstructive procedures after partial mastectomy. The authors analyzed the oncologic results of volume displacement surgery after partial mastectomy and their associations with various clinicopathologic factors. PATIENTS AND METHO...
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.1016/j.clbc.2016.06.018
更新日期:2017-02-01 00:00:00
abstract:BACKGROUND:The adoption of hypofractionated radiotherapy (HFRT) into clinical practice varies widely despite randomized trials and guidelines supporting its equivalence to conventional fractionated radiotherapy (CFRT) for certain patient populations. We assessed the use of HFRT at a single institution from 2011 to 2018...
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.1016/j.clbc.2020.03.006
更新日期:2020-10-01 00:00:00
abstract:BACKGROUND:It has been determined that axillary lymph node dissection after the detection of limited axillary lymph node metastasis does not improve the prognosis of patients with breast cancer. Thus, a need exists for less-invasive axillary surgery. However, it remains unclear whether a predictive model based on preop...
journal_title:Clinical breast cancer
pub_type: 杂志文章
doi:10.1016/j.clbc.2020.11.008
更新日期:2020-11-17 00:00:00
abstract:BACKGROUND:Nanosomal docetaxel lipid suspension formulation was developed to eliminate ethanol and polysorbate 80 from the currently used docetaxel (Taxotere) drug for treatment of cancer patients. NDLS clinical safety and efficacy was evaluated and compared with Taxotere at 75 mg/m(2) in metastatic breast cancer patie...
journal_title:Clinical breast cancer
pub_type: 杂志文章,随机对照试验
doi:10.1016/j.clbc.2013.09.011
更新日期:2014-06-01 00:00:00